Market Place
Sourcing Support
Inhibikase Therapeutics Reports Q3 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Inhibikase Closes Upto 275 M Financing For IkT-001Pro IN Hypertension
21 Oct 2024 //
GLOBENEWSWIRE
Inhibikase Announces $110M Placement For IkT-001Pro Trial
09 Oct 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics Reports Q2 Financial Results And Recent Activity
14 Aug 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics To Report Q2 2024 Results On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Inhibikase Completes Enrollment Of Phase 2 Trial For Risvodetinib In Parkinson’s
17 Jun 2024 //
GLOBENEWSWIRE
Inhibikase: Pipeline Expansion, R&D Program Updates
05 Jun 2024 //
GLOBENEWSWIRE
Inhibikase Prices $4M Priced At-Market Offering & Warrant Inducement
20 May 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics Announces Withdrawal Of S-1 Registration Statement
15 May 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics Reports Q1 Financial Results, Highlights Period Activity
15 May 2024 //
GLOBENEWSWIRE
Inhibikase IkT-001Pro PAH Treatment Pre-IND Outcomes
09 May 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics Updates Shareholders On Development Programs
18 Apr 2024 //
GLOBENEWSWIRE
Inhibikase Announces Pre-IND Meeting with the FDA for IkT-001Pro in PAH
03 Apr 2024 //
GLOBENEWSWIRE
Inhibikase Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib
07 Mar 2024 //
GLOBENEWSWIRE
Inhibikase Announces Full Outcomes of Pre-NDA Meeting with FDA for IkT-001Pro
28 Feb 2024 //
GLOBENEWSWIRE
Inhibikase Announces Outcomes of its Pre-NDA Meeting for Approval for IkT-001Pro
07 Feb 2024 //
GLOBENEWSWIRE
Inhibikase Announces Publication Highlighting Results from Ph 1 with Risvodetinib
29 Jan 2024 //
GLOBENEWSWIRE
Inhibikase Therapeutics Announces Planned Retirement of CFO Joseph Frattaroli
16 Jan 2024 //
GLOBENEWSWIRE
Inhibikase Issues Letter to Shareholders
19 Dec 2023 //
GLOBENEWSWIRE
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
04 Dec 2023 //
GLOBENEWSWIRE
Inhibikase Therapeutics Reports Third Quarter Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Inhibikase to Report Second Quarter Financial Results on November 14, 2023
07 Nov 2023 //
GLOBENEWSWIRE
Inhibikase to Report Third Quarter Financial Results on November 14, 2023
07 Nov 2023 //
GLOBENEWSWIRE
Inhibikase Highlights Functional Analysis from the 201 Trial of Risvodetinib
16 Oct 2023 //
GLOBENEWSWIRE
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib
04 Oct 2023 //
GLOBENEWSWIRE
Inhibikase Issues a Letter to Shareholders and Comments on Trading Activity
20 Sep 2023 //
GLOBENEWSWIRE
Inhibikase Announces Development of Novel Formulation of risvodetinib
24 Aug 2023 //
PR NEWSWIRE
Inhibikase to Present at the International Congress of Parkinson`s Disease
22 Aug 2023 //
PR NEWSWIRE
Inhibikase Initiates Development of Second Generation c-Abl inhibitors
21 Aug 2023 //
PR NEWSWIRE
Inhibikase Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
17 Aug 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Reports Second Quarter Financial Results
14 Aug 2023 //
PR NEWSWIRE
Inhibikase to Report Second Quarter Financial Results on August 14, 2023
07 Aug 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
17 Jul 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
29 Jun 2023 //
PR NEWSWIRE
Inhibikase Announces Selection of the Bioequivalent Dose of IkT-001
22 Jun 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign
21 Jun 2023 //
PR NEWSWIRE
Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
30 May 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Reports 1Q FYR & Highlights Recent Period Activity
15 May 2023 //
PR NEWSWIRE
Inhibikase Therapeutics to Report First Quarter Financial Results
08 May 2023 //
PR NEWSWIRE
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
04 May 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Provides Safety & Functional Update on its Ph 1/1b 101
26 Apr 2023 //
PR NEWSWIRE
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
21 Apr 2023 //
PR NEWSWIRE
Inhibikase Reports Full Year 2022 Financial Results
31 Mar 2023 //
PR NEWSWIRE
Inhibikase to Report Q4 and Full-Year 2022 Financial Results on March 31, 2023
23 Mar 2023 //
PR NEWSWIRE
Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023
16 Mar 2023 //
PR NEWSWIRE
Inhibikase Provides Interim Update on `501` Bioequivalence Study of IkT-001Pro
15 Mar 2023 //
PR NEWSWIRE
Inhibikase Announces FDA has Lifted the Full Clinical Hold on IkT-148009
08 Mar 2023 //
PR NEWSWIRE
Inhibikase clears another clinical hold, preps new phase 2 trial
08 Mar 2023 //
FIERCE BIOTECH
Inhibikase to Present at Alzheimer`s & Parkinson`s Drug Development Summit
15 Feb 2023 //
PR NEWSWIRE
Inhibikase Announces Closing of $10M Concurrent Registered Direct Offering
27 Jan 2023 //
PR NEWSWIRE
Inhibikase Announces FDA has Lifted Hold on IkT-148009 in Parkinson`s Disease
26 Jan 2023 //
PR NEWSWIRE
Inhibikase Therapeutics Announces $10M Concurrent Registered Direct Offering
25 Jan 2023 //
PR NEWSWIRE
Inhibikase Announces Dosing of First Subjects in `501` Bioequivalence Study
12 Dec 2022 //
PRNEWSWIRE
Inhibikase Provides Update to FDA Clinical Hold of IkT-148009 Programs
07 Dec 2022 //
PRNEWSWIRE
Inhibikase to Present at Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
PRNEWSWIRE
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
PRNEWSWIRE
Inhibikase stock sinks on FDA clinical hold of Parkinson`s drug
08 Nov 2022 //
FIERCEBIOTECH
Inhibikase to Present at Cambridge Institute`s Neurodegeneration Conference
12 Oct 2022 //
PRNEWSWIRE
Inhibikase to Present at the Grand Challenges in Parkinson`s Disease Conference
21 Sep 2022 //
PRNEWSWIRE
